ADCC News and Research

RSS

Tumor environments sculpt diverse natural killer cells for cancer therapies

For decades, natural killer (NK) cells have been classified into two main groups based on surface markers: one specialized for cytokine production and the other for direct killing.

4 Sep 2026

Different anti-PD-L1 antibodies show varied results in tumor growth inhibition

Immune checkpoint inhibitors (ICIs), a powerful form of immunotherapy, have revolutionized cancer treatment by unleashing the body's own immune system to fight tumors.

24 Jul 2025

Navigating the dual role of B cells in tumor immunity

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

3 Jun 2025

Avelumab and cetuximab combination shows promise in phase II skin cancer trial

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC).

1 Jun 2025

Decades of research push cytomegalovirus vaccine closer to reality

Researchers review decades of progress in human cytomegalovirus (HCMV) vaccine development, emphasizing challenges, innovative platforms, and the critical need for effective prevention strategies.

6 Jan 2025

Vaccines targeting chronic diseases show promise in combatting age-related conditions

Vaccine-based therapeutics for age-related disorders.

17 Apr 2024

Study shows potential for universal flu vaccine with broad antibody response

Study discusses the potential of universal influenza vaccines, emphasizing the importance of antibody breadth and Fc receptor (FcR) effector functions in protecting against various influenza strains, including those with pandemic potential.

15 Apr 2024

Therapeutic potential of CD20 x CD3 bispecific antibodies

On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials.

From Sino Biological Inc. 5 Apr 2024

Study links elevated BMI to weaker immune response post-SARS-CoV-2 infection

Researchers evaluated the impact of BMI elevation on humoral immunity levels against SARS-CoV-2.

6 Dec 2023

Next-generation ovarian cancer therapy: Engineered Vδ2 T cells show promise in preclinical trials

A prospective path for allogeneic cellular immunotherapies.

13 Nov 2023

Potential of COVID-19 convalescent plasma for future monoclonal antibodies against severe SARS-CoV-2 inflammation

Researchers report that convalescent plasma treatment is most effective in treating hospitalized COVID-19 patients.

17 Aug 2023

Study evaluates differences in humoral immune response against SARS-CoV-2 in infants versus mothers

Researchers comparatively evaluated humoral immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among infants and their mothers.

16 Aug 2023

People living with HIV respond well to COVID-19 infection and vaccination

Researchers examine the antibody response to natural infection or COVID-19 vaccination in individuals living with HIV infection.

7 Aug 2023

Study suggests SARS-CoV-2 vaccination in pregnancy induces diverging maternal and infant cord antibody functions

Researchers explored the differences in infant and maternal cord antibody functions between SARS-CoV-2 infection and vaccination during pregnancy.

4 May 2023

Phase 2 study shows safety and efficacy of new drug in men with high-risk prostate cancers

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

6 Apr 2023

Spike-induced humoral immunity and its association with antibody-dependent cellular cytotoxicity potency

A new study aimed to analyze the qualitative and quantitative impact of S-induced humoral immunity along with its ADCC capability in individuals who received a vaccination, recovered from an infection, or both.

14 Mar 2023

Clec9A-RBD immunization could trigger robust and sustained systemic and mucosal immune responses against rapidly evolving SARS-CoV-2 variants

Researchers assessed the impact of a single-dose dendritic cell vaccine candidate on immune responses against SARS-CoV-2.

23 Feb 2023

Researcher contextualizes a study on IgG4 anti-Spike levels after repeated SARS-CoV-2 mRNA vaccination

A researchers emphasized the need to reconsider mRNA COVID-19 vaccination strategies in the future,

9 Feb 2023

How do mutations in emergent SARS-CoV-2 Omicron variants affect viral function, human immunity, and recognition by therapeutic antibodies?

Researchers explored how mutations in emergent SARS-CoV-2 variants affect viral function, human immunity, and recognition by therapeutic antibodies.

19 Jan 2023

The binding and functional serologic responses to COVID-19 vaccination in children with history of MIS-C

Researchers evaluated the serological responses elicited by COVID-19 vaccinations in children who developed MIS-C following a previous SARS-CoV-2 infection.

23 Nov 2022